α-Synuclein Degrader Compound Screening Assay Service

Our cutting-edge α-synuclein (α-syn) degradation compound screening platform empowers you to rapidly identify promising drug candidates. By targeting and degrading α-synuclein, a key protein implicated in neurotoxic aggregate formation, you can pave the way for innovative treatments that may slow or even halt disease progression. As a leading neurobiology CRO, we offer unparalleled expertise and resources to support your research goals. Contact us today to learn how our platform can accelerate your discovery process.

Introduction

Compound Screening Assay

• High-Throughput Cell-Based Screening

Our newly developed cell line stably expresses α-syn, providing a robust and reliable platform for high-throughput screening. This innovative tool enables researchers to quantitatively assess the biological or biochemical activity of compounds aimed at reducing α-syn expression. Ideal for drug discovery and target identification, this cell line facilitates the efficient screening of large compound libraries and the selection of promising candidates for further evaluation.

Service Procedure

• Compound library preparation: Obtain compound libraries from commercial suppliers or collect test compounds provided by customers, and conduct preliminary screening.
• Cell culture and treatment: Use our newly developed cell lines stably expressing α-synuclein or other neuron-like cells to co-incubate the compounds with the cells.
• Fluorescence detection: Detect the aggregation of α-synuclein by combining Thioflavin T (ThT) with ELISA to screen out compounds with significant effects.
• Further verification: Perform cytotoxicity evaluation and functional verification on the screened compounds to ensure their safety and effectiveness.

Case Study: Cell-based α-Syn aggregation inhibitor screening assay.

This cell-based assay utilizes HeLa cells transiently expressing α-Synuclein-EGFP to create a robust model of α-Synuclein aggregation. Treatment with pre-formed fibrils (PFFs) of α-synuclein induces pathological aggregation, enabling the identification of compounds that inhibit this process. This assay is ideal for high-throughput screening and drug discovery for PD and related synucleinopathies.

Fig.1 α-Synuclein Aggregation Model for High-Throughput Drug Screening.^{2, 3}

By leveraging existing research outcomes and technological frameworks, we are able to deliver efficient and precise services, while also fostering innovation in the treatment of diseases such as PD. For further information regarding the products and services provided, project-specific consultation, and pricing, please submit an inquiry here.

References

1. Calabresi, Paolo, et al. "Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction."Cell death & disease 14.3 (2023): 176.
2. Hideshima, Makoto, et al. "Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson's disease." Scientific reports 12.1 (2022): 351.
3. Distributed under Open Access license CC BY 4.0, without modification.